What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
On April 6, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed that it has received notice from Takeda (NYSE: TAK) about the termination of the collaboration agreement on developing and commercializing DNL593. This move was due to some strategic reasons and is unrelated to the results on the efficacy or safety of the drug. Copyright: dolgachov / 123RF Stock Photo DNL593 is a progranulin replacement therapy that involves the use of Denali's Protein Transport Vehicle technology to deliver progranulin to the brain to treat frontotemporal dementia-granulin. Denali has been responsible for all the developmental activities and is going to resume full control over DNL593 and the intellectual property portfolio. As pointed out by Chief Executive Officer Ryan Watts, although the collaboration was important, full ownership of DNL593 is good news. The firm is still certain that the scientific principle and the evidence collected so far are strong. According to the plan, Denali will present t
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics (DNLI) had its price target lowered by Leerink Partners from $40.00 to $35.00. They now have an "outperform" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm) [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an "outperform" rating on the stock.MarketBeat
- Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) [Yahoo! Finance]Yahoo! Finance
DNLI
Earnings
- 2/26/26 - Beat
DNLI
Sec Filings
- 4/21/26 - Form 3/A
- 4/21/26 - Form DEFA14A
- 4/21/26 - Form ARS
- DNLI's page on the SEC website